drugset / Trial / NCT01004198

Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients

NCT01004198 ↗

Phase 2 Completed 51 enrolled Sangart
RandomizedParallel-groupQuadruple-blindTreatment

Summary

MP4OX is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. MP4OX is a pegylated hemoglobin-based colloid and and as a result of its molecular size and unique oxygen dissociation characteristics, targets oxygen delivery to ischemic tissues by selectively off-loading oxygen in tissues predisposed to low oxygen tension. Sangart is currently evaluating MP4OX to reduce organ dysfunction and failure in trauma patients with lactic acidosis due to severe hemorrhagic shock.

Timeline

Start
2009-12
Primary completion
2010-06
Completion
2010-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MP4OX Protein / enzyme biologic 250 ml —
Subject MP4OX Protein / enzyme biologic 500 ml —
Comparator Ringers Lactate solution Unknown 500 ml —

Indications